Cargando…

Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients

INTRODUCTION: Metabolic syndrome has been recognized as a predictor of cardiovascular diseases. Epicardial fat tissue (EFT) thickness has recently been shown to be a predictor of cardiovascular diseases in metabolic syndrome patients. Endocan is a novel molecule which is considered to be an early ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyuk, Banu, Cetin, Seher Irem, Erman, Hande, Sevinc, Samet, Bulut, Umit, Guzel, Savas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885812/
https://www.ncbi.nlm.nih.gov/pubmed/33644488
http://dx.doi.org/10.5114/amsad.2020.103031
_version_ 1783651676682452992
author Boyuk, Banu
Cetin, Seher Irem
Erman, Hande
Sevinc, Samet
Bulut, Umit
Guzel, Savas
author_facet Boyuk, Banu
Cetin, Seher Irem
Erman, Hande
Sevinc, Samet
Bulut, Umit
Guzel, Savas
author_sort Boyuk, Banu
collection PubMed
description INTRODUCTION: Metabolic syndrome has been recognized as a predictor of cardiovascular diseases. Epicardial fat tissue (EFT) thickness has recently been shown to be a predictor of cardiovascular diseases in metabolic syndrome patients. Endocan is a novel molecule which is considered to be an early marker of endothelial dysfunction. Our aim was to evaluate endocan serum levels for the first time in metabolic syndrome patients, in relation to EFT thickness. MATERIAL AND METHODS: The study included 44 patients with metabolic syndrome who had neither chronic kidney disease nor chronic inflammation and 26 healthy controls. Fasting blood samples were obtained from the groups. The serum levels of endocan were measured with a Sunred ELISA kit. EFT thickness of patients was measured by echocardiography. RESULTS: The serum endocan levels were significantly lower in the metabolic syndrome patients compared to the healthy controls (120.71 ±90.17 pg/ml vs. 414.59 ±277.57, p < 0.001). Metabolic syndrome patients demonstrated significantly higher EFT (p = 0.042). EFT thickness had a positive correlation with age (r = 0.397, p = 0.008) and weight (r = 0.010). However, there was no correlation with serum endocan (r = –0.021, p = 0.893) or other parameters. Regression analysis revealed that waist circumference is the parameter among metabolic syndrome criteria having the strongest relationship with serum endocan levels (β = –0.499, p = 0.21). CONCLUSIONS: EFT thickness was high in metabolic syndrome patients and can be a useful marker for cardiovascular risk assessment. However, serum endocan levels were found to be low and there was no correlation with EFT thickness. Large sample sized prospective studies are needed to clarify the relation of endocan levels with the other clinical indicators of cardiovascular risk in metabolic syndrome.
format Online
Article
Text
id pubmed-7885812
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-78858122021-02-26 Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients Boyuk, Banu Cetin, Seher Irem Erman, Hande Sevinc, Samet Bulut, Umit Guzel, Savas Arch Med Sci Atheroscler Dis Clinical Research INTRODUCTION: Metabolic syndrome has been recognized as a predictor of cardiovascular diseases. Epicardial fat tissue (EFT) thickness has recently been shown to be a predictor of cardiovascular diseases in metabolic syndrome patients. Endocan is a novel molecule which is considered to be an early marker of endothelial dysfunction. Our aim was to evaluate endocan serum levels for the first time in metabolic syndrome patients, in relation to EFT thickness. MATERIAL AND METHODS: The study included 44 patients with metabolic syndrome who had neither chronic kidney disease nor chronic inflammation and 26 healthy controls. Fasting blood samples were obtained from the groups. The serum levels of endocan were measured with a Sunred ELISA kit. EFT thickness of patients was measured by echocardiography. RESULTS: The serum endocan levels were significantly lower in the metabolic syndrome patients compared to the healthy controls (120.71 ±90.17 pg/ml vs. 414.59 ±277.57, p < 0.001). Metabolic syndrome patients demonstrated significantly higher EFT (p = 0.042). EFT thickness had a positive correlation with age (r = 0.397, p = 0.008) and weight (r = 0.010). However, there was no correlation with serum endocan (r = –0.021, p = 0.893) or other parameters. Regression analysis revealed that waist circumference is the parameter among metabolic syndrome criteria having the strongest relationship with serum endocan levels (β = –0.499, p = 0.21). CONCLUSIONS: EFT thickness was high in metabolic syndrome patients and can be a useful marker for cardiovascular risk assessment. However, serum endocan levels were found to be low and there was no correlation with EFT thickness. Large sample sized prospective studies are needed to clarify the relation of endocan levels with the other clinical indicators of cardiovascular risk in metabolic syndrome. Termedia Publishing House 2020-12-26 /pmc/articles/PMC7885812/ /pubmed/33644488 http://dx.doi.org/10.5114/amsad.2020.103031 Text en Copyright: © 2020 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Boyuk, Banu
Cetin, Seher Irem
Erman, Hande
Sevinc, Samet
Bulut, Umit
Guzel, Savas
Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title_full Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title_fullStr Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title_full_unstemmed Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title_short Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
title_sort evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885812/
https://www.ncbi.nlm.nih.gov/pubmed/33644488
http://dx.doi.org/10.5114/amsad.2020.103031
work_keys_str_mv AT boyukbanu evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients
AT cetinseherirem evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients
AT ermanhande evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients
AT sevincsamet evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients
AT bulutumit evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients
AT guzelsavas evaluationofserumendocanlevelsinrelationtoepicardialfattissuethicknessinmetabolicsyndromepatients